New Breastlight Data Confirms Accuracy in Detecting Malignant Tumors

Photography of Breastlight taken at Sunderland trial. Shadow on left breast represents increased blood supply (angiogenesis) associated with tumor growth. Confirmed by biopsy as malignant tumor of 2.2 cm. Right breast with no shadow confirmed as negative.


June 17, 2010 – Breastlight successfully detects malignant tumors and picks up lesions as small as 7 mm, according to data presented this week at the European Institute of Oncology's 12th Milan Breast Cancer Conference. [1]

The handheld device, for women to use at home, was tested in a trial at a breast clinic in Sunderland City Hospital involving 300 women. Patients were examined with Breastlight and findings compared to mammography, ultrasound and biopsy.

Breastlight detected 12 out of 18 confirmed malignant tumors, and correctly identified as negative 240 out of 282 breasts. [1] The device also detected malignant tumors as small as 7 mm. [1] Malignancies below 1.8 cm are considered non-palpable. [2]

“We were impressed with the sensitivity and specificity of the Breastlight device,” said Matei Dordea, specialist registrar at Sunderland City Hospital. “Mammography sensitivity falls between 60 and 90 percent and specificity falls between 75 and 95 percent. Breastlight’s sensitivity was 67 percent with specificity at 85 percent. We are not saying that Breastlight could replace mammography, but it can reliably pick up abnormal lumps which can be investigated to assess whether benign or malignant.”

The Sunderland team see Breastlight’s role in women who find palpation difficult: “Women who have confirmed recurrent cysts find it difficult to palpate. As benign cysts tend not to have a blood supply, they will not show up with Breastlight. However, if women feel new cysts they should always seek medical advice.”

Breastlight is a UK invention that works by shining a very bright but harmless red LED light through breast tissue. Veins and other blood vessels show up as dark lines, often referred to as the “map” of the breast. This is normal. If a woman detects dark spots or shadows, this is generally an indication that there is an abnormality. This could be the stimulation of blood vessels (angiogenesis) when a tumor is developing or a benign lesion such as a bruise or blood-filled cyst.

For more information: www.breastlight.com

References:

1. Iwuchukwu, O., Keaney, N., Dordea, M. “Analysis of Breastlight findings in patients with biopsies.” City Hospital Sunderland. Presentation given at the European Institute of Oncology’s 12th Milan Breast Cancer Conference
2. Canadian Cancer Society


Related Content

News | Breast Imaging

Dec. 01, 2025 — DeepHealth, a wholly owned subsidiary of RadNet, Inc., has launched the DeepHealth Breast Suite,2 an end ...

Time December 04, 2025
arrow
News | Mammography

Nov. 30, 2025 — At RSNA 2025, Siemens Healthineers will introduce new capabilities for its Mammomat B.brilliant ...

Time December 02, 2025
arrow
News | RSNA 2025

Dec. 2, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, will present 14 studies at RSNA ...

Time December 02, 2025
arrow
News | Mammography

Nov. 26, 2025 — GE HealthCare has announced it received FDA Premarket Authorization for Pristina Recon DL, an advanced ...

Time November 29, 2025
arrow
News | Ultrasound Imaging

Nov. 12, 2025 — GE HealthCare and DeepHealth, Inc., a wholly owned subsidiary of RadNet, Inc., have announced their ...

Time November 20, 2025
arrow
News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
News | RSNA 2025

Nov. 3, 2025 — QT Imaging Holdings has announced that its chief medical officer, Elaine luanow, MD, will host a seminar ...

Time November 04, 2025
arrow
News | Women's Health

Nov. 3, 2025 — —A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 ...

Time November 04, 2025
arrow
Subscribe Now